A study to compare ability to reduce pain and improve quality of life of pregabalin versus amitriptyline for diabetic neuropathic pain

A study to compare the efficacy,safety and Quality of life in patients with Moderate Diabetic Peripheral Neuropathic Pain on Pregabalin versus Amitriptyline at a tertiary care centre-A Randomised Control Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/095929

Enrollment

Registered

2025-10-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: G63- Polyneuropathy in diseases classified elsewhere

Interventions

Intervention1: Tab Pregabalin 75mg: tablet taken O.D in the night after food Control Intervention1: Tab Amitriptyline 25mg H S: HALF TABLET O.D AT NIGHT AFTER FOOD

Eligibility

Inclusion criteria

Inclusion criteria: Patients with moderate diabetic neuropathic pain

Exclusion criteria

Exclusion criteria: pregnancy lactation hepatic dysfunction renal dysfunction arryhthmias

Design outcomes

Primary

Measure	Time frame
Reduction in severity of Neuropathic pain assessed by NRS SCALETimepoint: Reduction in severity of Neuropathic pain assessed by NRS SCALE IN 6 WEEKS	—

Secondary

Measure	Time frame
Improvement of quality of life index with pain reduction assessed by NEUROQOL SCORETimepoint: 6 weeks	—

Countries

India

Contacts

Public ContactDr Chethana Amarnath

Banglore Medical College and Research Institute

Geethaanathramaih@gmail.com9886224085

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026